Skip to content
ETEN
Findshops
Politics

Medical Cannabis in France: Existing Patients Continue Under Transitional Rules

Illustrative cannabis plant, rather than French programme documentation

Updated 6 November 2026. France has worked towards permanent medical cannabis regulation for years, but steps announced in spring 2025 did not immediately establish a new system. For comparison, see Denmark’s permanent programme. As of autumn 2026, former pilot patients continued treatment under transitional arrangements, while the final framework still depended on health technology assessment and legislation.

What happened to the pilot programme?

Cannabis leaves in natural light
Illustrative photograph, rather than documentation from France’s programme. Photo: Jordan Bergendahl / Pexels.

France began its medical cannabis pilot in March 2021. It officially ended on 31 December 2024. No new patients had joined since 27 March 2024, but existing participants were allowed to continue treatment to avoid abrupt interruption.

The transition was originally due to end on 31 March 2026. Information verified by France’s public services portal on 14 September 2026 instead described an extension until three months after the relevant opinion from health assessment authority HAS. At this article’s update, the official guidance had not confirmed the opinion’s publication date.

Is medical cannabis generally available in France?

Not through a general permanent system. Continuing care for former pilot participants is not the same as every eligible new patient being able to begin treatment under permanent national rules. The pilot, transitional provisions and legislation prepared for future use must be distinguished.

In 2025, the planned system was described through regulations notified to the European Union, including requirements for quality, production, dispensing and medical supervision. Proposed requirements are not all equivalent to law already in force.

Which conditions did the pilot address?

It focused on limited indications where conventional treatment was insufficient or unsuitable. These included certain treatment-resistant epilepsies, neuropathic pain, some forms of spasticity linked to multiple sclerosis or other central nervous system disorders, certain cancer-treatment symptoms and palliative care.

This does not make cannabis universally effective for those conditions. Benefits and adverse effects depend on the preparation, active-substance content and the patient’s health.

What comes next?

France’s medical cannabis framework depends primarily on final regulations and health authority assessments. Before official implementation, a broad new prescription system cannot be promised or proposed products presented as generally available treatment.

Medical reform also does not generally legalise recreational cannabis use. These are separate legal questions.

Sources

Share article
REKLAAMIPIND
Your ad here

Advertising space available.

Get in touch ↗

Lisa kommentaar

Your email address will not be published. Required fields are marked *